Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
-
SciScore for 10.1101/2020.06.07.20124776: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: All the data received Institutional Review Board (IRB) approval by the Ethics Committee. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Case inclusion criteria: (1) cases were diagnosed with common COVID-19 within first three days after admission; (2) eligible cases were man and non-pregnant women; (3) age > 18 years old; (4) the SARS-CoV-2 nucleic acid were tested positive for the cases during the first three days after hospitalization; (5) the nucleic acid test of SARS-CoV-2 was continuous; (6) patients in the PPIs group were those who had used PPIs for at least 3 days before the SARS-CoV-2 … SciScore for 10.1101/2020.06.07.20124776: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: All the data received Institutional Review Board (IRB) approval by the Ethics Committee. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Case inclusion criteria: (1) cases were diagnosed with common COVID-19 within first three days after admission; (2) eligible cases were man and non-pregnant women; (3) age > 18 years old; (4) the SARS-CoV-2 nucleic acid were tested positive for the cases during the first three days after hospitalization; (5) the nucleic acid test of SARS-CoV-2 was continuous; (6) patients in the PPIs group were those who had used PPIs for at least 3 days before the SARS-CoV-2 clearance, while patients in the control group were those who had not used drugs to inhibit gastric acid secretion; (7) the daily dose of omeprazole was 20mg or 40mg, or the daily dose of rabeprazole was 20mg. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:limitations of study: The baseline data of our study lacked the viral load of SARS-CoV-2, but lymphocytes and CD4+ cells were included as the baseline reference and matching analysis was performed to make up for the deficiencies in our study, because it was proved that SARS-CoV-2 would affect the change of lymphocyte and CD4+ cell counts[22-24]. This study included only common COVID-19, due to the low number of severe and critical COVID-19 cases, and severe and critical cases were not included in the study; therefore, the study does not fully represent the effect of proton pump inhibitors on the course of severe or critical COVID-19. Since the subjects we included in this study are common COVID-19 cases, and PPIs have been used for a short time and at a conventional dose, so the study cannot represent the long-term or high-dose impact of PPIs on the course of COVID-19.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-